Cue Biopharma is trading at $29.89 (+5.84%), with the catalyst unconfirmed.
- No verified company-specific announcement is dated August 12, 2026.
- The latest official release, announced August 3, concerns CFO James M. Ahlers and the CUE-221 investigational new drug submission.
- Broader markets are modestly higher but do not clearly explain the gain; the move may reflect speculative biotech activity ahead of the expected August 18 earnings report.